In the context of prediabetes and established T2DM, analyses from large-scale clinical trials (ORIGIN and DEVOTE) of cardiovascular events in recent years revealed that the use of insulin did not lead to major cardiovascular outcomes or to increased HF hospitalization and HF recurrence [23–25]. This evidence concerns the gene INS and prediabetes syndrome.